June 2, 2008 - CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, announced that on June 6, 2008 it will present study data indicating that diabetic mice treated with iroxanadine healed from diabetic wounds nearly two times faster than untreated diabetic mice. These study results will be introduced by CytRx's Senior Vice President of Research and Development Shi Chung Ng, Ph.D., at the Third Congress of the World Union of Wound Healing Societies held in Toronto, Canada. During his presentation, Dr. Ng will discuss the method of action of iroxanadine, which is believed to repair damaged endothelial cells by amplifying molecular chaperones. Molecular chaperones are proteins that recognize for repair or mark for destruction other proteins that have misfolded in inappropriate, toxic shapes during conditions that are stressful to cells, such as during certain disease states. Small molecule amplifiers of the chaperone response, such as CytRx's clinical candidates iroxanadine and arimoclomol, have shown promising results in animal models of neurological impairment and diabetic complications... CytRx's Press Release -
